Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.53 |
| ▸ | MTOR | P42345 | 11/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925480 | 0.99 | PIK3CA (0.54) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8214040 | 0.88 | PIK3CA (0.54) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8214756 | 0.87 | PIK3CA (0.55) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8218355 | 0.86 | PIK3CA (0.38) | PIK3CAPIK3CDMTOR | |
| SCHEMBL8213961 | 0.86 | CA12 (0.47) | — | |
| SCHEMBL8212679 | 0.85 | PIK3CA (0.47) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8214218 | 0.85 | PIK3CA (0.66) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8214580 | 0.83 | PIK3CA (0.57) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8213051 | 0.81 | PIK3CA (0.53) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8213164 | 0.81 | PIK3CA (0.55) | PIK3CAPIK3CDMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |